Evidence map›Paper›PMID 12964886›Full record

ReviewDrugs & aging2003

Seizures in elderly patients with dementia: epidemiology and management.

Mario Mendez, Gerald Lim

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Drugs & aging, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04004702 (Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial), which is not on this map. Cited by 87 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 3 pooled it
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04004702 phase2unknown statusnot on this mapstarted 2020, after this paper: background citation

Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE) - A Phase II Exploratory Study

TypeinterventionalSponsorWalter Reed National Military Medical CenterRan2020 to 2025Enrolled65ConditionsAlzheimer DiseaseArmsLevetiracetam
3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 3 syntheses or guidelines pooled it, 225 citations in OpenAlex.

  1. Treatment of epilepsy for people with Alzheimer's disease.The Cochrane database of systematic reviews · 2021
    Pooled it
  2. Treatment of epilepsy for people with Alzheimer's disease.The Cochrane database of systematic reviews · 2018
    Pooled it
  3. Treatment of epilepsy for people with Alzheimer's disease.The Cochrane database of systematic reviews · 2016
    Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mario MendezDepartment of Neurology, The University of California at Los Angeles, Los Angeles, California 90073, USA.
Gerald Lim
University of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epileptic seizures occur in patients with dementia at a higher prevalence than among healthy elderly individuals. The incidence of seizures among patients with dementia varies with the aetiology of the dementing illness. In patients with Alzheimer's disease (the most common form of dementia), approximately 10-22% have at least one unprovoked seizure. Seizures usually occur in later stages of Alzheimer's disease, on average, > or =6 years into the course of the disease. Seizures in Alzheimer's disease are more likely to occur with early-onset disease, particularly if there is a familial presenilin I mutation. The incidence of seizures in other dementing diseases is less clear. There are special considerations regarding the management of seizures in the elderly with dementia. First, the presence of cognitive impairment may impede an accurate diagnosis of seizures. Clinicians may also mistake seizure manifestations for symptoms of the underlying dementia. Second, since most dementia patients are elderly, there are pharmacokinetic changes with aging that affect the use of antiepileptic drugs. Third, antiepileptic drugs have potential cognitive adverse effects that may worsen dementia. Although few studies are available, extrapolations from research in young people and elderly patients without dementia provide several recommendations for the management of seizures in patients with dementia: exclude symptomatic causes of seizures before committing to antiepileptic drug therapy; treat after a first seizure if there is evidence of focal neurological involvement or a risk of recurrent seizures; use antiepileptic drugs with minimal cognitive adverse effects, such as carbamazepine, valproic acid, gabapentin and lamotrigine; and use the lowest possible dosage and monitor antiepileptic drug levels, where possible.

Indexed as

AgedAnticonvulsantsCarbamazepineCase ManagementDementiaEpilepsyHumansAnticonvulsantsCarbamazepine

Identifiers

PMID12964886
OpenAlexW162134209

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.